Clinical Trial Update: Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 study evaluating erlotinib in patients with metastatic and/or recurrent head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED